The first cancer immunotherapy drug approved by the Food and Drug Administration (FDA) in 2011 was ipilimumab, a cytotoxic T-lymphocyte antigen 4 (CTLA4)-blocking monoclonal antibody (mAb) for metastatic melanoma. This evidence concerns the gene CTLA4 and cancer.